Enzymatic production of prebiotic xylooligosaccharides reveals anti-inflammatory properties, suggesting health benefits.
The enzymatic production of xylooligosaccharides (XOSs) from xylan-rich agricultural byproducts has gained attention as a sustainable and environmentally friendly approach. In this work, two forms of recombinant Bacillus subtilis xylanases, MBP-BsXynA11 (a fusion of a maltose-binding protein with the xylanase) and BsXynA11-His (the xylanase with a 10xHis-tag), were investigated for their ability to convert xylan into value-added XOS. Both enzymes exhibited similar temperature and pH optima at 60 °C and 6.5, with specific activities of 7,900 and 4,800 U/nmol, respectively. However, MBP-BsXynA11 demonstrated higher yields upon recombinant expression, as well as greater specificity and thermostability compared to BsXynA11-His. Optimal hydrolysis of xylan yielded 53% and 51% XOS for MBP-BsXynA11 and BsXynA11-His, respectively. The resulting XOS were water-soluble, with over 90% of the products consisting of xylobiose, xylotriose, and xylotetraose, while xylose accounted for less than 0.5%. Finally, XOS generated from MBP-BsXynA11 demonstrated both prebiotic and anti-inflammatory activities in human monocytes.
No takes yet. Share an insight, caveat, or question.
Cuong et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: